HK1232289A1 - 分揀蛋白作為針對情感/心境障礙的生物標記的用途 - Google Patents

分揀蛋白作為針對情感/心境障礙的生物標記的用途

Info

Publication number
HK1232289A1
HK1232289A1 HK17105802.8A HK17105802A HK1232289A1 HK 1232289 A1 HK1232289 A1 HK 1232289A1 HK 17105802 A HK17105802 A HK 17105802A HK 1232289 A1 HK1232289 A1 HK 1232289A1
Authority
HK
Hong Kong
Prior art keywords
sortilin
biomarker
mood disorders
affective mood
affective
Prior art date
Application number
HK17105802.8A
Other languages
English (en)
Inventor
．耶普森
．尼科耶爾
．莫斯
．彼得森
．厄斯特高
．格萊若普
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of HK1232289A1 publication Critical patent/HK1232289A1/zh

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/30—Psychoses; Psychiatry
    • G01N2800/304—Mood disorders, e.g. bipolar, depression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK17105802.8A 2014-02-12 2017-06-12 分揀蛋白作為針對情感/心境障礙的生物標記的用途 HK1232289A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA201400075 2014-02-12
PCT/EP2015/052506 WO2015121166A1 (en) 2014-02-12 2015-02-06 Use of sortilin as biomarker for affective/mood disorders

Publications (1)

Publication Number Publication Date
HK1232289A1 true HK1232289A1 (zh) 2018-01-05

Family

ID=52462923

Family Applications (1)

Application Number Title Priority Date Filing Date
HK17105802.8A HK1232289A1 (zh) 2014-02-12 2017-06-12 分揀蛋白作為針對情感/心境障礙的生物標記的用途

Country Status (6)

Country Link
US (1) US20160349276A1 (zh)
EP (1) EP3105594A1 (zh)
JP (1) JP2017508144A (zh)
CN (1) CN105980858A (zh)
HK (1) HK1232289A1 (zh)
WO (1) WO2015121166A1 (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016164608A1 (en) 2015-04-07 2016-10-13 Alector Llc Methods of screening for sortilin binding antagonists
CA2981851A1 (en) 2015-04-07 2016-10-13 Alector Llc Anti-sortilin antibodies and methods of use thereof
FR3057267A1 (fr) * 2016-10-11 2018-04-13 Centre National De La Recherche Scientifique - Cnrs - Procede de diagnostic/determination de l'efficacite de traitement de la depression
WO2019094596A1 (en) * 2017-11-09 2019-05-16 The Trustees Of Columbia University In The City Of New York Biomarkers for efficacy of prophylactic treatments against stress-induced affective disorders
BR112019022666A2 (pt) 2018-07-13 2020-09-01 Alector Llc anticorpos antissortilina e métodos de uso dos mesmos
CN111351945B (zh) * 2020-03-18 2021-04-23 东南大学 维生素d结合蛋白作为标志物在精神疾病抑郁症诊断中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8703125B2 (en) * 2008-12-19 2014-04-22 H. Lundbeck A/S Modulation of the Vps10p-domain receptor family for the treatment of mental and behavioural disorders
GB0903417D0 (en) * 2009-02-27 2009-04-08 Cambridge Entpr Ltd Biomarkers
GB0922240D0 (en) * 2009-12-21 2010-02-03 Cambridge Entpr Ltd Biomarkers
GB201021502D0 (en) * 2010-12-20 2011-02-02 Cambridge Entpr Ltd Biomarkers

Also Published As

Publication number Publication date
US20160349276A1 (en) 2016-12-01
CN105980858A (zh) 2016-09-28
EP3105594A1 (en) 2016-12-21
JP2017508144A (ja) 2017-03-23
WO2015121166A1 (en) 2015-08-20

Similar Documents

Publication Publication Date Title
EP3359171C0 (en) USING AKKERMANSIA MUCINIPHILA TO TREAT INFLAMMATORY CONDITIONS
IL251584B (en) Dihydropyrrolopyridines ror–gamma inhibitors
IL246902B (en) Dihydropyrrolopyridine ror–gamma inhibitors
AP2016009496A0 (en) Substituted spirocydic inhibitors of autotaxin
HK1232289A1 (zh) 分揀蛋白作為針對情感/心境障礙的生物標記的用途
GB201410646D0 (en) Methods of increasing sequencing accuracy
PL3122349T3 (pl) Kompozycje do leczenia samotrawienia
IL258593B (en) Compounds for the treatment of subculture disorders
SG11201708181RA (en) Methods for the treatment of inflammatory disorders
PL3152576T3 (pl) Zastosowanie tm9sf4 jako biomarkera egzosomów powiązanych z nowotworem
EP3046995A4 (en) REFINING WASTE OILS
ZA201802544B (en) Methods for total synthesis of resolvin e1
GB201510544D0 (en) New synthesis of tapentadol-hci intermediates
GB201516418D0 (en) Treatment of acute inflammatory disorders
GB201516140D0 (en) Treatment of acute inflammatory disorders
GB201521543D0 (en) Methods for the treatment of inflammatory disorders
GB201409995D0 (en) Purification of oils
PL3137475T3 (pl) Oczyszczanie epidaunorubicyny
GB201513993D0 (en) Methods for the treatment of inflammatory disorders
GB201513345D0 (en) Methods for the treatment of Inflammatory disorders
GB201507113D0 (en) Methods for the treatment of inflammatory disorders
GB201506419D0 (en) Methods for the treatment of inflammatory disorders
GB201506229D0 (en) Methods For the Treatment Of Inflammatory Disorders
GB201414314D0 (en) Manufacture of graphene
GB201417192D0 (en) Deposition of graphene